Side by side
Retatrutide vs Tesamorelin / Ipamorelin
Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| Retatrutide | Tesamorelin / Ipamorelin | |
|---|---|---|
| What it is | An investigational once-weekly triple agonist acting on the GLP-1, GIP and glucagon receptors. Not approved anywhere. | An approved GHRH analogue paired with a ghrelin agonist. Sold at three different splits, which matters more here than in most blends. |
| EvidenceHow much human evidence exists, not how well it works. | Early human trials | Preclinical |
| Regulatory statusReviewed 2026-08-12 | Investigational. Not approved for human use in any jurisdiction. Sold only as a research chemical, with no manufacturing standard behind that label. | Tesamorelin is approved by the FDA for HIV-associated lipodystrophy. Ipamorelin is approved nowhere, and the mixture is approved nowhere. Sold as a research chemical at several ratios. |
| Routes | Subcutaneous | Subcutaneous |
| Half-life | 144 hours | Not recorded |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $1.25/mg | $3.44/mg |
| Median per mg | $5.17/mg | $6.54/mg |
| Vendors with a price | 37 | 23 |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze. | Refrigerated at 2–8 °C and used within about 30 days. A blend cannot be split. A contaminated vial takes every component with it. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.